News
CRL
227.55
-1.10%
-2.54
Relative Strength Alert For Charles River Laboratories International
NASDAQ · 2d ago
Here's Why You Should Retain Charles River (CRL) Stock Now
NASDAQ · 2d ago
CHARLES RIVER LABORATORIES LAUNCHES ALTERNATIVE METHODS ADVANCEMENT PROJECT TO REDUCE RELIANCE ON ANIMAL TESTING
Reuters · 2d ago
CHARLES RIVER LABORATORIES INTERNATIONAL - INITIATIVE FOCUSES ON INNOVATION, PARTNERSHIPS, ADVOCACY AS PART OF $500 MLN INVESTMENT IN DRIVING CHANGE
Reuters · 2d ago
Weekly Report: what happened at CRL last week (0408-0412)?
Weekly Report · 3d ago
Press Release: Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
Charles River Laboratories International, Inc. Will release first-quarter 2024 financial results on Thursday, May 9, before the market opens. A conference call has been scheduled to discuss this information on May 9 at 8:30 a.m. ET. Charles River provides products and services to pharmaceutical and biotechnology companies.
Dow Jones · 6d ago
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
Charles River Laboratories International, Inc. Will release first-quarter 2024 financial results on Thursday, May 9th, before the market opens. A conference call has been scheduled to discuss this information. Charles River provides products and services to help pharmaceutical and biotechnology companies accelerate their research and drug development efforts.
Barchart · 04/12 07:00
Charles River Laboratories International, Inc.'s (NYSE:CRL) Price Is Out Of Tune With Earnings
Charles River Laboratories International, Inc. (NYSE:CRL) has a price-to-earnings ratio of 26.8x. The company is trading at a high P/E compared to the rest of the U.S. Market. Its negative earnings growth of late may be the reason for the high valuation. However, the company's growth is not in line with the growth of the market.
Simply Wall St · 04/11 14:31
Charles River, Axovia to collaborate on gene therapy development
Charles River Laboratories International, Inc. To collaborate on gene therapy development with Axovia Therapeutics. Charles River will manufacture high quality gene of interest plasmid to support development of gene therapies to treat cilia dysfunction diseases called ciliopathies. The company has entered into a collaboration with axovia.
Seeking Alpha · 04/09 14:48
CHARLES RIVER LABORATORIES INTERNATIONAL INC: HQ PLASMID DNA PRODUCTION TO SUPPORT PHASE I TRIALS FOR GENE THERAPY TARGETING BARDET-BIEDL SYNDROME
Reuters · 04/09 12:00
Weekly Report: what happened at CRL last week (0401-0405)?
Weekly Report · 04/08 09:22
Charles River To Perform Plasmid Production For Ship Of Theseus
GMP grade plasmid DNA to serve as a direct therapeutic targeting various indications. Charles River and Ship of Theseus will leverage Charles River's expertise to manufacture the active drug substance for its lead candidate. The company is developing biologics based on the HOX family of transcription factors.
Benzinga · 04/04 12:09
U.S. RESEARCH ROUNDUP-Ally Financial, GE Vernova, Navient
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Ally Financial, GE Vernova, Navient and Navient are among the companies. Analysts cut ratings and target prices on several companies on Wednesday. Some analysts raised their targets for the companies, others cut them.
Reuters · 04/03 07:28
CHARLES RIVER LABORATORIES INTERNATIONAL INC <CRL.N>: BAIRD RAISES TARGET PRICE TO $282 FROM $268
Reuters · 04/03 05:30
These are the most neglected stocks within each sector - BofA
These are the most neglected stocks within each sector of the S&P 500 (SP500) BofA analysts published “the most neglected” stocks -- or least crowded -- within each of the 11 sectors. Crowding is when a large number of investors take the same position in a stock.
Seeking Alpha · 04/01 17:41
CHARLES RIVER LABORATORIES INTERNATIONAL INC <CRL.N>: EVERCORE ISI RAISES TARGET PRICE TO $300 FROM $265
Reuters · 04/01 11:42
Weekly Report: what happened at CRL last week (0325-0329)?
Weekly Report · 04/01 09:21
Charles River Laboratories International (NYSE:CRL) Has A Pretty Healthy Balance Sheet
Charles River Laboratories International, Inc. Has US$2.62b of debt. The company's net debt is 2.4 times its earnings before interest and tax. Debt is an important factor in assessing a company's ability to pay off its debt. Charles River Laboratories international recorded free cash flow worth 61% of its EBIT in the last year. The balance sheet is a good place to look at to see if a company has a problem with debt.
Simply Wall St · 03/27 13:12
Charles River (CRL) Extends Gene Therapy Deal With NUS Medicine
NASDAQ · 03/26 13:39
Charles Riv Labs Intl Inc: [Amend]Statement of changes in beneficial ownership of securities
Press release · 03/25 22:03
More
Webull provides a variety of real-time CRL stock news. You can receive the latest news about Charles Riv Labs Intl Inc through multiple platforms. This information may help you make smarter investment decisions.
About CRL
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions.